Hilda E. Ghadieh, Raghd Abu Helal, Harrison T. Muturi, Daniella D. Issa, Lucia Russo, Simon L. Abdallah, John A. Najjar, Fabian Benencia, Guillermo Vazquez, Wei Li, Sonia M. Najjar – 3 September 2020 – Patients with nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) commonly develop atherosclerosis through a mechanism that is not well delineated. These diseases are associated with steatosis, inflammation, oxidative stress, and fibrosis. The role of insulin resistance in their pathogenesis remains controversial.

Olaf Tyc, Christian Jansen, Robert Schierwagen, Frank Erhard Uschner, Mads Israelsen, Sabine Klein, Cristina Ortiz, Christian P. Strassburg, Stefan Zeuzem, Wenyi Gu, Sandra Torres, Michael Praktiknjo, Stephan Kersting, Melanie Langheinrich, Jacob Nattermann, Florence Servant, Manimozhiyan Arumugam, Aleksander Krag, Benjamin Lelouvier, Tobias J. Weismüller, Jonel Trebicka – 3 September 2020

Heinz Zoller, Sonja Wagner, Benedikt Schaefer – 3 September 2020

3 September 2020

Alcohol-associated liver disease (ALD) is the leading cause of cirrhosis worldwide. Harmful drinking, especially among youth and women, is increasing.  A global alliance and discussion about effective public health strategies is needed.

Zhe Li, Xinyuan Lu, Yanfang Liu, Jingjing Zhao, Shengzhe Ma, Haoxiang Yin, Shenglin Huang, Yingjun Zhao, Xianghuo He – 1 September 2020

Craig Lammert, Chengsong Zhu, Yun Lian, Indu Raman, George Eckert, Quan‐Zhen Li, Naga Chalasani – 1 September 2020 – Drug‐induced liver injury (DILI) sometimes presents with an autoimmune hepatitis‐like phenotype (AI‐DILI), and it is challenging to distinguish it from de novo autoimmune hepatitis (AIH). We conducted a study to identify autoantibodies unique to AI‐DILI by profiling serum autoantibodies.

Julie Steen Pedersen, Marte Opseth Rygg, Viggo Bjerregaard Kristiansen, Beth Hærstedt Olsen, Reza Rafiolsadat Serizawa, Jens Juul Holst, Sten Madsbad, Lise Lotte Gluud, Flemming Bendtsen, Nicolai Jacob Wewer Albrechtsen – 1 September 2020 – Nonalcoholic fatty liver disease (NAFLD) is associated with impaired hepatic actions of glucagon and insulin. Glucagon and amino acids are linked in an endocrine feedback circuit, the liver–alpha cell axis, that may be disrupted by NAFLD.

Salvatore Piano, Carmine Gambino, Elia Vettore, Valeria Calvino, Marta Tonon, Patrizia Boccagni, Enrico Gringeri, Giacomo Germani, Patrizia Burra, Umberto Cillo, Paolo Angeli – 1 September 2020

Faouzi Saliba, Sébastien Dharancy, Ephrem Salamé, Filoména Conti, Daniel Eyraud, Sylvie Radenne, Térésa Antonini, Olivier Guillaud, Jean Guguenheim, Martine Neau‐Cransac, Eléonora Demartin, Guillaume Lasailly, Christophe Duvoux, Rodolphe Sobesky, Audrey Coilly, Sylvie Tresson, Valérie Cailliez, Olivier Boillot, Georges Philippe Pageaux, Didier Samuel, Yvon Calmus, Jérôme Dumortier – 31 August 2020 – Longterm use of a calcineurin inhibitor (CNI)–based regimen is one of the major reasons for chronic renal failure in liver transplantation recipients (LTRs).